This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at: https://awmsg.nhs.wales/.
awmsg logo



cholic acid (Orphacol®)


Reference No. 929

Publication date:
27/02/2014


Appraisal information

cholic acid (Orphacol®) 50 mg capsule
cholic acid (Orphacol®) 250 mg capsule


Company: Laboratoires CTRS
BNF category: Nutrition and blood
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 26/02/2014

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, cholic acid (Orphacol®) cannot be endorsed for use within NHS Wales for the treatment of inborn errors in primary bile acid synthesis due to 3β-Hydroxy-Δ5-C27-steroid oxidoreductase deficiency or Δ4-3-Oxosteroid-5β-reductase deficiency in infants, children and adolescents aged one month to 18 years and adults.
Statement of Advice (SOA)
Download